Inside The Planning Of Audentes' Future Manufacturing Facility

By Erin Harris, Editor-In-Chief, Cell & Gene
Follow Me On Twitter @ErinHarris_1

Audentes Therapeutics’ Sanford, NC, facility, which will manufacture the company’s portfolio of adeno-associated virus (AAV)-based gene therapies aimed at targeting serious rare neuromuscular diseases, is slated to be operational this year.

Donald Wuchterl, Audentes’ SVP of technical operations, and Don Mather, executive director, manufacturing & operations site head at Audentes, give some details on the planning stages, equipment needs, challenges, and status of this massive project.